ONM-405 / OncoNano Medicine - LARVOL DELTA

Ultra-pH sensitive nanoparticles increase therapeutic index of IL-2-Fc (SITC 2022) - "Background Aldesleukin (IL-2) is clinically approved for the treatment of melanoma and renal cancer, but its use is restricted by short half-life and dose limiting toxicities. The enhanced safety profile of ONM-405 is further validated in non-human primates. Conclusions ON-BOARD technology offers an effective tumor-directed on/off switch achieving antitumor efficacy in solid tumors in response to the acidic TME, while minimizing systemic toxicity of IL-2-Fc in normal tissues."

Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • IFNG • IL2

OncoNano Medicine to Present Data on Novel Development Candidates at the Society for Immunology of Cancer (SITC) Annual Meeting (Businesswire) - "An oral and poster presentation by Dr. Qiang Feng detail new pre-clinical data for ONM-405, an IL-2-Fc construct formulated with OncoNano’s proprietary ON-BOARD™ polymeric-micelle delivery system....OncoNano will also present a poster detailing data from studies involving the use of the ON-BOARD™ platform for encapsulation and delivery of bispecific T cell engagers. In addition, a poster will feature new preclinical data of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications."

Preclinical • Oncology